United States: Human Drug Compounding: FDA Issues Four Guidance Documents

FDA had a busy holiday season, issuing two final guidance documents and two draft guidance documents for industry related to human drug compounding right before the start of the new year. These guidance documents cover prescription requirements under Section 503A of the Federal Food, Drug, and Cosmetic Act (FFDCA); compounding and repackaging of radiopharmaceuticals; and electronic drug product reporting by Outsourcing Facilities under the FFDCA.

Final Guidance for Industry: Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act

This final guidance sets out (1) a definition for "valid prescription order"; (2) rules for when a drug can be compounded pursuant to Section 503A of the FFDCA; (3) rules for when a drug compounded pursuant to Section 503A can be distributed; and (4) guidelines for compounding for office stock and office use.

Compounding Pursuant to a Valid Prescription Order

The final guidance defines a "valid prescription order" as one which is from "a licensed physician or other licensed practitioner authorized by state law to prescribe drugs." The guidance also states that "a valid order or notation made by a prescriber" on a patient's medical record while the patient is in an inpatient setting could be included as a valid prescription order for compounding under Section 503A of the FFDCA. Lastly, the definition includes orders made by a physician who also compounds a drug when properly noted in his or her patient's chart. Regardless of where the valid prescription order is made, the guidance states that to meet the patient-specific requirements of 503A, it must include the identity of the patient. In other words, spreadsheets and orders that include physician names but do not include patient-specific identifying information are not considered valid prescription orders under the guidance.

When a Drug Can Be Compounded Pursuant to Section 503A

A drug can be properly compounded under Section 503A of the FFDCA in two situations: (1) after receipt of a valid prescription order; or (2) before receipt of the valid prescription order, also called "anticipatory compounding," when this compounding satisfies very specific exceptions. Unless the compounding falls within an exception, the compounding physician or pharmacist cannot fill the order without receipt of a valid, patient-specific prescription order.

As mentioned above, to compound before the receipt of a valid, patient-specific prescription order, the compounding physician or pharmacist must be engaging in anticipatory compounding. Under the guidance, anticipatory compounding is permitted when (1) there is a history of receiving valid orders for the compounded drug; or (2) the order is generated within an established relationship between the prescriber or patient and the compounder. Anticipatory compounding must be done in limited quantities, under the belief the compounder will receive a patient-specific order in the context of an existing relationship.

The guidance does not address whether a 503A compounder has exceeded the "limited quantity condition" if the compounder follows the product's BUD requirements and does not retain more than a 30-day supply for distribution, and if the amount compounded is based on historical data for that particular product. It should also be noted that, according to the guidance, FDA will not examine whether a 503A compounder is exceeding the exceptions if it follows the 30-day limitation.

When a 503A Compounded Drug Can Be Distributed

As previously mentioned, under the guidance, a 503A compounded drug may be distributed only pursuant to a patient-specific prescription order. In the guidance, FDA specifically noted that some states' boards of pharmacy permit distribution of compounded drugs via prescriptions without an individual patient's name. While this is permitted behavior in some states, FDA stated that it is not permissible to distribute using such a prescription under 503A. However, it should be noted that a properly licensed and cGMP-compliant 503B Outsourcing Facility may distribute compounded drugs using such a prescription.

Draft Guidance for Industry: Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities

Compounding of radiopharmaceuticals has a long and interesting history. Section 503A of the FFDCA specifically excludes radiopharmaceuticals meaning they are not afforded the exemptions that other drug products compounded by the same entity are, and therefore do not meet the FFDCA exceptions for a "new drug." Similarly, repackaged radiopharmaceuticals are not exempt from any provisions of the FFDCA.

This guidance, related to compounding of radiopharmaceuticals by state-licensed nuclear pharmacies and federal facilities, stipulates FDA's intention not to take action against state-licensed nuclear pharmacies and federal facilities for compounding radiopharmaceuticals in violation of Section 505 (new drug approval requirements), Section 502(f)(1) (labeling with adequate directions for use), and Section 501(a)(2)(B) (current good manufacturing practice (CGMP) requirements) under the following conditions.

Radiopharmaceutical Compounding That Involves Manipulation Other Than Minor Deviations

  • The product is compounded by or under the direct supervision of a nuclear pharmacist in a facility holding a Resident Acoustic Mixer (RAM);
  • The product is distributed pursuant to a patient-specific prescription;
  • If compounded in anticipation of a prescription, the product is not compounded in a quantity that exceeds expected demand based on historical prescription information, and it is not distributed prior to receipt of the patient-specific prescription;
  • If the product is compounded with bulk substances, those substances comply with an applicable USP or NF monograph;
  • If the product is compounded with bulk substances, those substances must be accompanied by a COA from the original manufacturer;
  • The product is compounded in compliance with USP <795> or USP <797>;
  • The product does not appear on an FDA withdrawn or removed-from-the-market list;
  • The product is not essentially a copy of a marketed FDA-approved radiopharmaceutical;
  • The product is not on the list of products presenting demonstrable difficulties to compound;
  • The product is not sold or transferred by any entity other than the one compounding it;
  • The product is only distributed in states where the compounding of such product meets all applicable state requirements; and
  • The product is compounded in compliance with NRC requirements.

Radiopharmaceutical Compounding That Constitutes Minor Deviations, and Repackaging

  • The product is compounded from an FDA-approved drug product;
  • No additional substances are included in the product unless they are consistent with the FDA-approved labeling;
  • If the product is compounded (not repackaged), the compounding constitutes a "minor deviation";
  • The compounding or repackaging occurs by or under the direct supervision of a licensed nuclear pharmacist in a RAM facility;
  • Compounding or repackaging occurs in compliance with USP <795> or USP <797>;
  • The product is compounded or repackaged in compliance with NRC requirements;
  • The product is distributed only in states where the compounding or repackaging of such product meets all applicable state requirements; and
  • The product must not be sold or transferred by any entity other than the one compounding or repackaging it.

Comments on the draft guidance are due February 27, 2017.

Draft Guidance for Industry: Compounding and Repackaging of Radiopharmaceuticals by Outsourcing Facilities

FDA released the following separate guidance to address the question of how the agency will view compounding of radiopharmaceuticals by a 503B entity. Specifically, this draft guidance addresses the circumstances under which an Outsourcing Facility may compound or repackage radiopharmaceuticals.

Compounding

Importantly, FDA states that radiopharmaceuticals are not expressly excluded from the definition of "compounding" in Section 503B of the FFDCA. By contrast, radiopharmaceuticals are expressly excluded from the definition in Section 503A of the FFDCA. For this reason, FDA clarifies that "the conditions of section 503B of the [FFDCA] apply to radiopharmaceuticals compounded by an entity that is registered with FDA as an Outsourcing Facility." (Guidance, at lines 117-122.) In addition, the FDA has developed a number of policies applicable only to the compounding of radiopharmaceuticals by Outsourcing Facilities, including those applicable to:

  • Bulk drug substances used in compounding radiopharmaceuticals under Section 503B. FDA initially solicited nominations for bulk drug substances to include on its bulk drug substances list, but only one radiopharmaceutical was nominated, likely because there were still outstanding questions about the regulation of this type of compounding. For this reason, FDA has opened nominations for the 503B bulk drug substances list for radiopharmaceuticals.
  • Compounding radiopharmaceuticals that are essential copies of approved drugs. FDA indicates that it does not intend to take action against an Outsourcing Facility for compounding a radiopharmaceutical that would otherwise meet the definition of an "essential copy of an approved drug" if (a) the product is not compounded from bulk drug substances; (b) there is a "minor deviation" from the approved product labeling; and (c) all drugs are compounded in compliance with all other requirements of Section 503B. A "minor deviation" is defined as "a change from the approved labeling in radioactivity, volume, and/or the step-by-step procedures made when compounding the radiopharmaceutical from an FDA-approved drug product in a patient-ready dose." (Guidance, at lines 211-214)

Repackaging

FDA clarifies what it considers to be repackaging. Specifically, the draft guidance states:

FDA regards repackaging as the act of taking a finished drug product, including a radiopharmaceutical, from the container in which it was distributed by the original manufacturer and placing it into a different container without further manipulation of the drug. Repackaging also includes the act of placing the contents of multiple containers (e.g., vials) of the same finished drug product into one container, as long as the container does not include other ingredients. If a radiopharmaceutical is manipulated in any other way, including if it is reconstituted, diluted, mixed, or combined with another ingredient, that act is not considered repackaging.

(Guidance, at lines 133-140)

The draft guidance also sets out FDA policy on repackaging radiopharmaceuticals:

  • Repackaged drugs are not subject to Section 503B. Thus, repackaged radiopharmaceuticals are not subject to Section 503B or eligible for the exemptions under Section 503B.
  • If an entity only repackages drug products, including radiopharmaceuticals, it does not meet the definition of an Outsourcing Facility.
  • If an entity does meet the definition of an Outsourcing Facility, and the entity also repackages radiopharmaceuticals, "FDA does not intend to take action for violations of sections 505 and 502(f)(1) of the [FFDCA] when the Outsourcing Facility repackages radiopharmaceuticals" if specific conditions are met:

    • The repackaged radiopharmaceutical is approved under Section 505 of the FFDCA;
    • Repackaging occurs under the direct supervision of a licensed, authorized nuclear pharmacist in an Outsourcing Facility with a RAM license;
    • Repackaging occurs in accordance with CGMP requirements;
    • The product is not on a withdrawn or removed-from-the-market list;
    • The repackaged product is not sold or transferred by an entity other than the one that repackaged it;
    • The product is distributed only in states where the production of the radiopharmaceutical meets all state requirements;
    • Repackaging occurs in compliance with all applicable NRC requirements;
    • Specific labeling requirements are met;
    • The product is included on the required biannual report to FDA; and
    • The Outsourcing Facility reports serious adverse events for the repackaged radiopharmaceutical.

Note that the draft guidance does not address the following:

  • "Mixing, reconstituting, combining, diluting, or repackaging of a radiopharmaceutical, or other such acts, performed in accordance with directions contained in the FDA-approved labeling";
  • PET drugs;
  • Non-radiopharmaceuticals;
  • Radioactive biological products subject to the PHSA;
  • Radiopharmaceuticals for animals;
  • Compounding or repackaging of radiopharmaceuticals by non-outsourcing facilities.

(Guidance, at lines 26-34)

Comments on the draft guidance are due February 27, 2017.

Final Guidance for Industry: Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act

This final guidance outlines how FDA-registered Outsourcing Facilities must submit drug product reports pursuant to Section 503B of the FFDCA.

Who Must Report and What Must be Reported

A drug product report must be submitted to FDA upon initial registration as an Outsourcing Facility and twice each year (June and December). This includes zero reporting if the Outsourcing Facility has not compounded a drug product in the previous six-month period.

The following information must be included:

  • The active ingredient and strength of active ingredient per unit – "strength" means the strength of the active ingredient per dose;
  • The source of the active ingredient;
  • The National Drug Code (NDC) number of the source drug or bulk active ingredient, if available – this must be submitted in the standard format of 10 numerical digits;
  • The dosage form and route of administration;
  • The package description of the smallest saleable package for distribution;
  • The number of individual units produced (based on the smallest individual saleable packages); and
  • The NDC number of the final product, if assigned.

When to Report

Reports must be filed upon initial registration and twice a year (June and December). The initial report must list products compounded in the previous six months, not including the month of registration. June reporting must include products compounded from December 1 through May 31. December reporting must include products compounded from June 1 through November 30.

How to Report

Product reporting must be submitted using the FDA electronic reporting system, and information must be submitted in the structured product labeling (SPL) format unless FDA has granted a waiver. Outsourcing Facilities must use the Human Compounded Drug Label document type when making electronic submissions. More information about electronic submissions is available at the FDA website.

Confidentiality of Reporting Information

Outsourcing Facility registration information is publically available; however, specific product reporting may be exempt from inspection "unless the Secretary finds that such an exemption would be inconsistent with the protection of the public health." This guidance clarifies that FDA does not intend to exempt some of the product reporting from inspection – including the name of the Outsourcing Facility, the address of the Outsourcing Facility, the name of the active ingredient, the strength of the active ingredient per unit, the dosage form, the package description, and the NDC of the final product (if assigned) – because it would be inconsistent with the protection of the public health. FDA states that:

[t]his information is generally required on product labels or publicly available, but publication of this information will facilitate product recalls when they are necessary, and assist the public in finding outsourcing facilities that have compounded certain drug products, particularly drugs in shortage. FDA intends to publish this information on our Web site. FDA does not intend to publish information about a drug submitted in a product report if an outsourcing facility notes in the report that it has not distributed the drug and has not advised any person of its intent or ability to compound the drug.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.